Free tool
FAERS Monitor: Herceptin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103792 or its brand name (Herceptin, Trastuzumab). Reports on generic versions are filed under their own applications.
Reports
68,519
Serious
58,724
86% of reports
Hospitalization
19,884
Death reported
8,254
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea6,727
- alopecia5,032
- nausea4,582
- fatigue4,414
- off label use4,273
- death3,634
- disease progression3,611
- myelosuppression3,242
- vomiting3,054
- dyspnoea2,795
- pyrexia2,541
- asthenia2,348
- neutropenia2,209
- neuropathy peripheral2,161
- pain2,068
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 372 |
| 2005 | 377 |
| 2006 | 529 |
| 2007 | 587 |
| 2008 | 654 |
| 2009 | 973 |
| 2010 | 1,225 |
| 2011 | 1,190 |
| 2012 | 2,644 |
| 2013 | 2,889 |
| 2014 | 2,389 |
| 2015 | 2,682 |
| 2016 | 2,839 |
| 2017 | 4,453 |
| 2018 | 5,684 |
| 2019 | 4,963 |
| 2020 | 5,107 |
| 2021 | 4,903 |
| 2022 | 4,743 |
| 2023 | 5,016 |
| 2024 | 6,903 |
| 2025 | 4,330 |
| 2026 | 3,067 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,985,640 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelosuppressionSignal | 3,242 | 30.3 | 29.2 | 83,599 |
| disease progressionSignal | 3,611 | 9.6 | 9.3 | 27,224 |
| alopeciaSignal | 5,032 | 8.0 | 7.8 | 30,531 |
| neuropathy peripheralSignal | 2,161 | 7.1 | 6.8 | 11,138 |
| neutropeniaSignal | 2,209 | 5.1 | 4.8 | 7,106 |
| diarrhoeaSignal | 6,727 | 3.2 | 3.1 | 10,522 |
| pyrexiaSignal | 2,541 | 2.3 | 2.2 | 1,807 |
| vomitingSignal | 3,054 | 2.0 | 1.9 | 1,552 |
| asthenia | 2,348 | 1.9 | 1.8 | 1,051 |
| nausea | 4,582 | 1.8 | 1.7 | 1,622 |
| fatigue | 4,414 | 1.7 | 1.7 | 1,448 |
| dyspnoea | 2,795 | 1.5 | 1.5 | 505 |
| off label use | 4,273 | 1.5 | 1.5 | 740 |
| death | 3,634 | 1.3 | 1.3 | 255 |
| pain | 2,068 | 1.0 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.